CD40LG and melanoma: Further bolstering the promise of vaccine approaches for improving OMM outcomes, a pilot study employing the intratumoral delivery of an adenovector CD40L transfection strategy has been conducted in dogs with malignant melanoma, and following vaccination, resected melanoma tissues had B and T lymphocytes trafficking through the tumor parenchyma indicating the existence of an immune-inflamed profile (146).